Interneuron anti-obesity agent dexfenfluramine to receive FDA review Sept. 28.
Executive Summary
INTERNEURON OBESITY THERAPY DEXFENFLURAMINE TO RECEIVE FDA REVIEW at the Sept. 28 meeting of the Endocrinologic & Metabolic Drugs Advisory Committee, Interneuron announced Aug. 14. Interneuron submitted an NDA for the serotonin release and reuptake inhibitor for treatment of obesity associated with carbohydrate craving in May 1993.